Please use this identifier to cite or link to this item:
Title: Optimised protocols to generate high titre lentiviral vectors using a novel transfection agent enabling extended HEK293T culture following transient transfection and suspension culture
Authors: Suleman, S
Fawaz, S
Roberts, T
Ellison, S
Bigger, B
Themis, M
Keywords: lentivirus;transient transfection;gene therapy;suspension culture;HEK293T
Issue Date: 11-Jan-2024
Publisher: Eslevier
Citation: Suleman, S. et al. (2024) 'Optimised protocols to generate high titre lentiviral vectors using a novel transfection agent enabling extended HEK293T culture following transient transfection and suspension culture', Journal of Virological Methods, 325, 114884, pp. 1 - 9. doi: 10.1016/j.jviromet.2024.114884.
Abstract: Copyright © 2024 The Author(s). HIV-1 based lentiviral viruses are considered powerful and versatile gene therapy vectors to deliver therapeutic genes to patients with hereditary or acquired diseases. These vectors can efficiently transduce a variety of cell types when dividing or non-dividing to provide permanent delivery and long-term gene expression. Demand for scalable manufacturing protocols able to generate enough high titre vector for widespread use of this technology is increasing and considerable efforts to improve vector production cost-effectively, is ongoing. Current methods for LV production mainly use transient transfection of producer cell lines. Cells can be grown at scale, either in 2D relying on culturing producer cells in multi-tray flask cell culture factories or in roller bottles or can be adapted to grow in 3D suspensions in large batch fermenters. This suits rapid production and testing of new vector constructs pre-clinically for their efficacy, particle titre and safety. In this study, we sought to improve lentiviral titre over time by testing two alternative commercially available transfection reagents Fugene® 6 and Genejuice® with the commonly used polycation, polyethyleneimine. Our aim was to identify less cytotoxic transfection reagents that could be used to generate LV particles at high titre past the often used 72 h period when vector is usually collected before producer cell death is caused due to post transfection cytotoxicity. We show that LV could be produced in extended culture using Genejuice® and even by transfected cells in glass flasks in suspension. Because this delivery agent is less toxic to 293 T producer cells, following optimisation of transfection we found that LV can be harvested for more than 10 days at high titre. Using our protocol, titres of 109 TU/ml and 108 TU/ml were routinely reached via traditional monolayer conditions or suspension cultures, respectively. We propose, this simple change in vector production enables large volumes of high titre vector to be produced, cost effectively for non-clinical in vivo and in vitro applications or for more stringent downstream clinical grade vector purification.
Description: Data availability statement: The data presented in this paper is available from the corresponding author upon reasonable request.
Authors contributed equally to this work.
ISSN: 0166-0934
Other Identifiers: ORCID iD: Saqlain Suleman
ORCID iD: Terry Roberts
ORCID iD: Michael Themis
Appears in Collections:Dept of Life Sciences Research Papers

Files in This Item:
File Description SizeFormat 
FullText.pdfCopyright © 2024 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license ( MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons